Predicting Lung Cancer Survival Using Probabilistic Reclassification of TNM Editions With a Bayesian Network.


Journal

JCO clinical cancer informatics
ISSN: 2473-4276
Titre abrégé: JCO Clin Cancer Inform
Pays: United States
ID NLM: 101708809

Informations de publication

Date de publication:
05 2020
Historique:
entrez: 12 5 2020
pubmed: 12 5 2020
medline: 1 9 2021
Statut: ppublish

Résumé

The TNM classification system is used for prognosis, treatment, and research. Regular updates potentially break backward compatibility. Reclassification is not always possible, is labor intensive, or requires additional data. We developed a Bayesian network (BN) for reclassifying the 5th, 6th, and 7th editions of the TNM and predicting survival for non-small-cell lung cancer (NSCLC) without training data with known classifications in multiple editions. Data were obtained from the Netherlands Cancer Registry (n = 146,084). A BN was designed with nodes for TNM edition and survival, and a group of nodes was designed for all TNM editions, with a group for edition 7 only. Before learning conditional probabilities, priors for relations between the groups were manually specified after analysis of changes between editions. For performance evaluation only, part of the 7th edition test data were manually reclassified. Performance was evaluated using sensitivity, specificity, and accuracy. Two-year survival was evaluated with the receiver operating characteristic area under the curve (AUC), and model calibration was visualized. Manual reclassification of 7th to 6th edition stage group as ground truth for testing was impossible in 5.6% of the patients. Predicting 6th edition stage grouping using 7th edition data and vice versa resulted in average accuracies, sensitivities, and specificities between 0.85 and 0.99. The AUC for 2-year survival was 0.81. We have successfully created a BN for reclassifying TNM stage grouping across TNM editions and predicting survival in NSCLC without knowing the true TNM classification in various editions in the training set. We suggest binary prediction of survival is less relevant than predicted probability and model calibration. For research, probabilities can be used for weighted reclassification.

Identifiants

pubmed: 32392098
doi: 10.1200/CCI.19.00136
pmc: PMC7265790
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

436-443

Références

J Thorac Oncol. 2007 Aug;2(8):706-14
pubmed: 17762336
CA Cancer J Clin. 2008 May-Jun;58(3):180-90
pubmed: 18460593
J Thorac Oncol. 2010 Nov;5(11):1779-83
pubmed: 20975377

Auteurs

Melle S Sieswerda (MS)

Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands.
Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands.

Inigo Bermejo (I)

Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands.

Gijs Geleijnse (G)

Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands.

Mieke J Aarts (MJ)

Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands.

Valery E P P Lemmens (VEPP)

Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands.

Dirk De Ruysscher (D)

Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands.

André L A J Dekker (ALAJ)

Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands.

Xander A A M Verbeek (XAAM)

Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH